Time to Vaccination After Rituximab (RTX) Discontinuation in Patients with anti–Aquaporin–4 Antibody–Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): A Post-Hoc Analysis of the CHAMPION-NMOSD Trial (P11-8.011)
To characterize the time from last RTX dose to the first administered meningococcal vaccine in patients from the CHAMPION-NMOSD trial previously on RTX.
Authors
- Kerstin R. Allen (ORCID: https://orcid.org/0009-0004-9286-6158)
- Jeffrey L. Bennett (ORCID: https://orcid.org/0000-0002-3346-1394)
- Aram Zabeti (ORCID: https://orcid.org/0000-0002-0424-7460)
- Shamik Bhattacharyya (ORCID: https://orcid.org/0000-0001-8047-3622)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Michael Levy
- Ukwen Apoji
Institutions
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Cincinnati (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208553
- Citations
- 1
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.39